Viridian Therapeutics, Inc. VRDN Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$104.9M+12.8% | -$120.36M-248% | -$34.6M+65.7% | -$100.74M-15.9% | -$86.91M-9.0% | ||
| $121K+0.8% | $120K+9.1% | $110K-2.7% | $113K-3.4% | $117K-4.9% | ||
| $13.39M+11.7% | $11.99M+6.6% | $11.25M+3.7% | $10.84M+6.1% | $10.22M+13.9% | ||
| -$119.65M-404% | -$23.75M+71.9% | -$84.61M-12.3% | -$75.37M+18.7% | -$92.65M-26.3% | ||
| $23K-90.4% | $240K+89.0% | $127K+202% | $42K-51.2% | $86K-24.6% | ||
| $77.26M+123% | -$339.42M-369% | $126.08M+66.5% | $75.72M-24.3% | $100.06M+259% | ||
| $6.36M-98.4% | $405.91M+3,639% | $10.86M+1,321% | $764K-91.7% | $9.21M-74.1% | ||
| -$36.04M-184% | $42.74M-18.3% | $52.32M+4,618% | $1.11M-93.3% | $16.62M+117% | ||
| -$119.68M-399% | -$23.99M+71.7% | -$84.74M-12.4% | -$75.42M+18.7% | -$92.74M-26.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viridian Therapeutics, Inc.'s cash flow data come from?
- Every line is extracted from Viridian Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.